Search Results 2001-2010 of 19633 for hemoglobin

1. Neurology - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

2. Performance-enhancing drugs: Know the risks - Mayo Clinic

   It also raises the levels of the protein in red blood cells that carries oxygen to the body's organs, called hemoglobin. Taking erythropoietin improves how ...

3. Temsirolimus and Bevacizumab in Treating Patients with Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Note: direct bilirubin and international normalized ratio (INR) for ...

4. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

   Hemoglobin(a) ≥9 g/dL;; Platelets(b) ≥100,000/mm3 (≥100 × 109/L);; ANC(c) ≥1000/mm3 (≥1.0 × 109/L). Hematologic (Coagulation Factors):. INR/PTd <1.5 ULN ...

5. A Study to Test Nivolumab with Usual Chemotherapy Treatment or Usual Chemotherapy Treatment Alone to Treat Recurrent or Metastatic Nasopharyngeal Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (transfusion is accepted. Erythropoietin dependency not accepted) (within 14 days prior to registration). Total bilirubin ≤ 1.5 x ...

6. A Study To Assess The Safety And Tolerability Of CFT7455 In Relapsed/Refractory Non-Hodgkin's Lymphoma Or Multiple Myeloma - Mayo Clinic

   - Hemoglobin ≥8.0 g/dL - ALT and AST ≤3.0 x upper limit of normal (ULN); except for subjects who have tumor infiltration of the liver, where ALT or AST ...

7. Oncology (Medical) - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

8. A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; In subjects transfused before study entry, transfusion must be ≥ 14 days prior to start of therapy to establish adequate hematologic ...

9. Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer - Mayo Clinic

   - Hemoglobin ≥ 9.0 gm/dL - Platelets ≥ 100,000/mcL - Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert ...

10. Publications - Mark J. Spangehl, M.D. - Mayo Clinic

    Routine Postoperative Hemoglobin and Hematocrit Tests Are Unnecessary Following Primary Total Hip and Knee Arthroplasty. Arthroplast Today. 2024 Dec; 30 ...